Ingredient or product comparison
Wolverine Stack GHK-Cu: Recovery Protocol Comparison
GHK-Cu Monotherapy Collagen remodeling, MMP activation, antioxidant gene expression 8–12 weeks Daily (acute phase), 3–4×/week (maintenance) Best for isolated collagen degradation (skin aging, minor tendon wear) without active inflammation or vascular compromis
This source-based comparison does not add ratings or recommend a winner.
- GHK-Cu Monotherapy
- Collagen remodeling, MMP activation, antioxidant gene expression
- 8–12 weeks
- Daily (acute phase), 3–4×/week (maintenance)
- Best for isolated collagen degradation (skin aging, minor tendon wear) without active inflammation or vascular compromise
- BPC-157 Monotherapy
- Angiogenesis, NO pathway stabilization, gut-barrier integrity
- 4–8 weeks
- Twice daily (250–500mcg per dose)
- Optimal for GI issues, localized soft tissue injuries, or vascular-limited healing. Less effective for structural remodeling
- TB-500 Monotherapy
- Actin binding, NF-κB downregulation, cell migration
- 8–12 weeks (loading + maintenance)
- Twice weekly (loading), weekly (maintenance)
- Strongest anti-inflammatory profile. Preferred for systemic inflammation or injuries where immune overactivation is primary
- Wolverine Stack (all three)
- Collagen synthesis + angiogenesis + inflammation control
- 8–16 weeks total
- GHK-Cu daily, BPC-157 twice daily, TB-500 twice weekly
- Comprehensive multi-pathway targeting. Justified when injury involves structural damage, vascular compromise, and persistent inflammation simultaneously
- PRP Injection + Rehab
- Growth factor delivery, platelet-derived signaling
- Single injection + 6–12 week rehab
- One-time or 2–3 injections spaced 4–6 weeks
- Standard orthopedic approach. Less targeted than peptide stacks but better evidence base and insurance coverage
- Conservative Management (rest, PT, NSAIDs)
- Symptom control, guided loading, inflammation suppression
- 12–16 weeks
- N/A (therapy sessions 2–3×/week)
- Baseline comparison. Effective for grade I/II injuries but slower timeline and higher re-injury risk in tendons and ligaments